$9.34
0.74%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US67080M1036
Symbol
NRIX

Nurix Therapeutics Inc Stock price

$9.34
-2.55 21.45% 1M
-6.11 39.55% 6M
-9.50 50.42% YTD
-15.66 62.64% 1Y
-6.47 40.92% 3Y
-14.06 60.09% 5Y
-9.67 50.87% 10Y
-9.67 50.87% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.07 0.74%
ISIN
US67080M1036
Symbol
NRIX
Industry

Key metrics

Basic
Market capitalization
$714.0m
Enterprise Value
$228.3m
Net debt
positive
Cash
$485.8m
Shares outstanding
76.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.1 | 7.5
EV/Sales
2.6 | 2.4
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
78.7%
Return on Equity
-36.7%
ROCE
-44.7%
ROIC
-319.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$88.4m | $95.2m
EBITDA
$-212.8m | $-238.0m
EBIT
$-230.5m | $-272.0m
Net Income
$-207.3m | $-232.0m
Free Cash Flow
$-225.8m
Growth (TTM | estimate)
Revenue
41.8% | 74.6%
EBITDA
-27.2% | -21.1%
EBIT
-28.7% | -27.7%
Net Income
-25.6% | -19.9%
Free Cash Flow
-113.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-240.8% | -249.9%
EBIT
-260.8%
Net
-234.6% | -243.6%
Free Cash Flow
-255.5%
More
EPS
$-2.5
FCF per Share
$-3.0
Short interest
19.8%
Employees
286
Rev per Employee
$190.0k
Show more

Is Nurix Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Nurix Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Nurix Therapeutics Inc forecast:

21x Buy
88%
3x Hold
13%

Analyst Opinions

24 Analysts have issued a Nurix Therapeutics Inc forecast:

Buy
88%
Hold
13%

Financial data from Nurix Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
May '25
+/-
%
88 88
42% 42%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 48 48
8% 8%
55%
- Research and Development Expense 270 270
38% 38%
306%
-213 -213
27% 27%
-241%
- Depreciation and Amortization 18 18
49% 49%
20%
EBIT (Operating Income) EBIT -230 -230
29% 29%
-261%
Net Profit -207 -207
26% 26%
-235%

In millions USD.

Don't miss a Thing! We will send you all news about Nurix Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nurix Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, Hans van Houte, chief financial officer, John Northcott, chief commerci...
Positive
Seeking Alpha
about 2 months ago
NRIX's Bexobrutideg shows impressive ORR for refractory CLL/WM. I believe this positions it as a potential best-in-class BTK degrader in a sizable TAM. Nurix Therapeutics also works with other big pharma like Gilead, Sanofi, and Pfizer to expand its promising targeted protein degradation IP franchise. I estimate their cash and marketable securities provide roughly 1.9 years of cash runway based...
Neutral
GlobeNewsWire
about 2 months ago
Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM)
More Nurix Therapeutics Inc News

Company Profile

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Head office United States
CEO Arthur Sands
Employees 286
Founded 2009
Website www.nurixtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today